Citations |
Blood Adv. 2022 Jan 14;bloodadvances.2021005948.<br/>Blood. 2019 Jan 3;133(1):70-80.<br/>Breast Cancer Res Treat. 2020 Jan;179(2):337-347.<br/>Cancer Lett. 2021 Oct 13;S0304-3835(21)00520-6.<br/>Carbohydr Polym. 2024 Feb 15, 326, 121637.<br/>Cell Biosci. 2020 Feb 12;10:16.<br/>Cell Biosci. 2022 Aug 2;12(1):122.<br/>Cell Biosci. 2022 Dec 30;12(1):210.<br/>Front Immunol. 2021 Oct 15;12:699478.<br/>Front Oncol. 2021 Jul 13;11:704042.<br/>Genes Dis. 1 July 2021.<br/>J Clin Invest. 2021 Dec 15;131(24):e140436.<br/>J Immunother Cancer. 2022 Mar;10(3):e003402.<br/>J Oncol. 2022 Apr 29;2022:1515416.<br/>Mol Cancer. 2023 Mar 30;22(1):64.<br/>Mol Carcinog. 2024 Apr 17<br/>Mol Syst Biol. 2023 Dec 18.<br/>RSC Adv., 2019, 9, 6409-6418<br/>Science. 2017 Dec 1;358(6367):eaan4368.<br/>Theranostics. 2020 Jan 1;10(4):1531-1543.<br/>Université de Lausanne. 2024 Feb 7.<br/>Front Oncol. 2022 Sep 8:12:944537.<br/>[1]Liu N, et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. Mol Cancer Ther. 2013 Nov;12(11):2319-30. |
Product Description |
Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2, 000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity[1]. |